| Japanese |
|---|
| Title | バセドウ病の131I治療患者における副甲状腺機能亢進症 (hyperparathyroidism) の発症について (第1報) |
|---|
| Subtitle | 原著 |
|---|
| Authors | 土屋武彦*, 伊藤國彦*, 村田紀** |
|---|
| Authors(kana) | |
|---|
| Organization | *伊藤病院, **千葉県がんセンター疫学研究部 |
|---|
| Journal | 核医学 |
|---|
| Volume | 33 |
|---|
| Number | 7 |
|---|
| Page | 729-735 |
|---|
| Year/Month | 1996/7 |
|---|
| Article | 原著 |
|---|
| Publisher | 日本核医学会 |
|---|
| Abstract | 「要旨」 外部放射線がHyperparathyroidism (HPT) を発生させる要因として作用することが示唆されている. そこで本研究は131IがHPTが発生の要因になるかどうかを知るために, バセドウ病で131I治療患者 (RI群) と抗甲状腺剤のみの治療患者 (ATD群) での血中Ca値とParathyroid hormone (PTH-M) 量とを測定した. RI群2,954例と, ATD群では, 530例について血中Ca値を測定し, 10.0mg/dl以上の値を示した症例262例と29例についてPTH-Mを測定した結果, RI群では58例 (2.50%), ATD群3例 (1.19%) が, 正常の上限値560pg/ml値を超えた値を示した. この差は統計的に有意であった. ただし, 追跡期間を加味した観察人年で比較すると, 統計的には有意性が認められなくなった. これらの結果を総合すると, PTH-M≧560pg/mlの出現頻度からみて, 131IがHPT発生の要因となる可能性があることと, 年齢の因子も重要であることが認められた. |
|---|
| Practice | 臨床医学：一般 |
|---|
| Keywords | Hyperparathyroidism, Basedow disease, 131I therapy, Parathyroid hormone, Calcium. |
|---|
| English |
|---|
| Title | An Evaluation of the Incidence of Hyperparathyroidism after 131I Treatment for Basedow Disease (Part I) |
|---|
| Subtitle | |
|---|
| Authors | Takehiko TSUCHIYA*, Kunihiko ITO*, Motoi MURATA** |
|---|
| Authors(kana) | |
|---|
| Organization | *Ito Hospital, **Division of Epidemiology, Chiba Cancer Center Research Institute |
|---|
| Journal | The Japanese Journal of nuclear medicine |
|---|
| Volume | 33 |
|---|
| Number | 7 |
|---|
| Page | 729-735 |
|---|
| Year/Month | 1996/7 |
|---|
| Article | Original article |
|---|
| Publisher | THE JAPANESE SOCIETY OF NUCLEAR MEDICINE |
|---|
| Abstract | It is known that external radiation can act as a developing factor in hyperparathyroidism (HPT). To clarify whether or not 131I acts as a factor of developing HPT or not, levels of calcium and parathyroid hormone in the blood were studied in 2,954 cases of patients treated with 131I (RI group) and 530 cases treated with antithyroid drugs (ATD group). The calcium level was measured in all cases treated with 131I and / or antithyroid drugs. PTH-M (parathyroid hormone) was measured in 262 cases of the RI group and 29 cases of the ATD group which showed levels over 10mg/dl of calcium. Fifty-eight cases (2.50%) in the RI group and three cases (1.19%) in the ATD group showed over 560pg/ml PTH-M, which is the highest normal value. The increase in incidence of cases with over 560pg/ml PTH-M in the RI group versus that of the ATD group is statistically significant. However, there is no statistically significant difference in the annual incidence when the follow-up period is taken into account, because the follow-up period differed between the two groups. The incidence of cases with 560pg/ml of PTH-M was higher in the older patients than in the younger patients. These results suggest that 131I treatment for Basedow disease affects increase in the development of HPT after treatment and that the age factor is also important in the above fact. |
|---|
| Practice | Clinical medicine |
|---|
| Keywords | Hyperparathyroidism, Basedow disease, 131I therapy, Parathyroid hormone, Calcium. |
|---|